New Immunotherapy Plus Chemotherapy Before Lung Cancer Surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of an immunotherapy drug (IBI363) plus chemotherapy before surgery in people with Stage III lung cancer that can't be removed at first. The goal is to shrink the tumor so it can be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have Stage III non-small cell lung cancer that cannot be removed with surgery.
- You cannot have certain gene changes in your tumor (like EGFR or ALK) that are treated with targeted therapy.
- You must have good organ function (kidneys, liver, heart) and be well enough to walk around and take care of yourself (ECOG 0-1).
- You must not have received any prior chemotherapy or other cancer drugs for this lung cancer.
- You must not have an autoimmune disease or severe heart/lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This Phase 2 trial tests an “immunotherapy” medicine given before surgery for stage III non-small cell lung cancer. The goal is to shrink the cancer and make curative surgery more successful while monitoring safety and response.
This trial tests a combination of chemotherapy and immunotherapy given before surgery for stage II or III non-small cell lung cancer. Doctors will look at biomarkers in your blood and tissue to see how the cancer responds, which could help guide future treatments.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy given before surgery to remove stage III lung cancer. The goal is to shrink the tumor and improve survival chances by boosting your immune system to fight the cancer.
This trial tests combining chemotherapy with immunotherapy before surgery for people with stage III non-small cell lung cancer that has a PD-L1 level of 1% or higher. The goal is to see if this approach can improve outcomes.
This trial tests whether giving an immune-boosting drug (Tα1) along with chemotherapy and immunotherapy before surgery helps people with stage II-IIIB non-small cell lung cancer that can be removed. It aims to see if this combination makes the cancer shrink more and improves outcomes.
Hear when a new Unresectable Stage III Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.